Biologics Manufacturing Scale and AI-Powered Discovery: Twin Pillars of Market Expansion

Biologics market was valued at $435.12 billion in 2024 and is projected to reach $983.94 billion by 2035, growing at a CAGR of 7.7% during the forecast period (2025–2035). Increasing investments in biologics manufacturing are among the major growth factors for the expansion of the biologics market, as they directly address major needs such as scalability and access. As the demand for biologics such as mAbs, cell and gene therapies continues to rise, companies such as Samsung Biologics, WuXi Biologics, Biocon, and Lotte Biologics are making significant investments in manufacturing facilities to increase production capacity and meet rising global healthcare needs. For instance, in July 2025, WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction had begun for a new modular Drug Product (DP) facility, which will become part of the company’s CRDMO hub in Singapore. Under the partnership between WuXi Biologics and Pharmadule Morimatsu, 470 modular components are being manufactured at Morimatsu's plant in Changshu City before being shipped to Singapore's Tuas Biomedical Park for installation.  Once completed, the building will be one of the largest modular biologics DP facilities across the globe, covering roughly 30,000 square meters of space. Furthermore, in June 2025, UCB, a global biopharmaceutical firm, announced plans for a large investment in a new, advanced biologics production facility in the US.  The initiative is projected to serve UCB's expanding number of patients in the US while generating a total economic impact of around $5 billion.

Browse the full report description of “Biologics Market Size, Share & Trends Analysis Report by Source (Microbial, Mammalian, and Others) by Product Type (Monoclonal Antibodies (mAbs), Vaccines, Recombinant Proteins, Gene Therapy, Cell Therapy and Others) by Application (Therapeutics, Diagnostics, Research Applications and Preventive), By Manufacturing Type (In-house Manufacturing, Contract Manufacturing) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/biologics-market

In recent years, there has been an increase in the use of AI to accelerate and improve the development of new drugs, including biologics. AI platforms can analyze vast amounts of data to discover new targets and optimize compounds, significantly lowering prices and timeframes. Companies such as AMD and Nvidia (via BioNeMo) are making significant investments in AI platforms for drug discovery. For instance, in January 2025, Absci Corporation and AMD established a collaborative partnership to use AMD InstinctTM accelerators and ROCmTM software to power Absci's extensive de novo antibody design models and other important AI drug discovery workloads. Additionally, AMD plans to invest $20 million in Absci under a private investment in public equity (PIPE) arrangement, highlighting the increasing need for advanced AI applications in drug discovery. The strategic alliance enables Absci to achieve its aim of delivering better biologics for patients faster by offering optimal AI solutions for complex biological models that provide superior results, lower infrastructure costs, and faster innovation cycles.  

Recent Developments 

• In August 2025, the FDA approved Papzimeos (zopapogene imadenovec-drba), a non-replicating adenoviral vector-based immunotherapy for the treatment of adult patients with recurrent respiratory papillomatosis (RRP). RRP is a rare, chronic condition characterized by persistent human papillomavirus (HPV) 6 or 11 infection, which results in the development of benign tumors in the respiratory tract, most commonly the larynx.

• In July 2025, the FDA granted accelerated approval to linvoseltamab-gcpt (Lynozyfic, Regeneron Pharmaceuticals, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Source

o By Product Type

o By Application

o By Manufacturing Type

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - AbbVie Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biologic Market Report Segment

By Source

• Microbial
• Mammalian
• Others (Insect cells, Transgenic animals/plants)

By Product Type

• Monoclonal Antibodies (mAbs)
• Vaccines
• Recombinant Proteins
• Gene Therapy
• Cell Therapy
• Others (Allergy Immunotherapy, Hormones)

By Application

• Therapeutics
• Diagnostics
• Research Applications
• Preventive

By Manufacturing Type

• In-house Manufacturing
• Contract Manufacturing (CMOs/CDMOs)

Global Biologic Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biologics-market